Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Chronic autoimmune neuropathies like CIDP and MMN are treated with IVIG, but optimal dosing is unclear.
• Antibody-mediated dysfunction at nodes of Ranvier may cause rapid conduction block, responding quickly to immunotherapy.
• The transient effects of IVIG suggest a need for sustained therapeutic IgG levels.

Purpose of the Study:

• To investigate the hypothesis that therapeutic IgG competes with autoantibodies.
• To explore individualized IgG levels for optimal treatment of autoimmune neuropathies.
• To assess methods for maintaining continuous high serum IgG levels.

Main Methods:

• Review of recent electrophysiology and immunology studies.
• Analysis of clinical reports on IVIG efficacy and duration.
• Exploration of frequent IVIG dosing and weekly subcutaneous IgG administration.
• Utilizing patient-reported grip strength and disability measurements via electronic reporting.

Main Results:

• Small case series suggest stabilization of neuromuscular function with frequent IVIG or weekly subcutaneous IgG.
• Individualized IgG levels may be necessary for optimal therapeutic effects.
• Home-based electronic monitoring can assess response duration and extent.

Conclusions:

• Individualizing immunoglobulin therapy regimens may enhance efficacy and minimize disability in autoimmune neuropathies.
• This approach could help identify patients who do not respond to standard treatment.
• Maintaining optimal serum IgG levels is crucial for sustained neuromuscular function.